Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria

Francis Varaine¹, Lorenzo Guglielmetti^{1

2}, Carole D Mitnick³

Affiliations

Comment

Francis Varaine et al. Am J Respir Crit Care Med. 2017.

. 2017 Dec 1;196(11):1490-1491.

doi: 10.1164/rccm.201705-0988LE.

Francis Varaine¹, Lorenzo Guglielmetti^{1

2}, Carole D Mitnick³

No abstract available

Comment on

Eligibility for the Shorter Multidrug-Resistant Tuberculosis Regimen: Ambiguities in the World Health Organization Recommendations.
Varaine F, Guglielmetti L, Huerga H, Bonnet M, Kiria N, Sitienei JK, Rich M, Mitnick CD. Varaine F, et al. Am J Respir Crit Care Med. 2016 Oct 15;194(8):1028-1029. doi: 10.1164/rccm.201605-1080LE. Am J Respir Crit Care Med. 2016. PMID: 27739887 No abstract available.
Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria.
Barry PM, Lowenthal P, True L, Henry L, Schack G, Wendorf K, Flood J, Shah N. Barry PM, et al. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1488-1489. doi: 10.1164/rccm.201701-0013LE. Am J Respir Crit Care Med. 2017. PMID: 28665681 No abstract available.